<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33115537</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-5960</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Acta neuropathologica communications</Title><ISOAbbreviation>Acta Neuropathol Commun</ISOAbbreviation></Journal><ArticleTitle>Intracellular dynamics of Ataxin-2 in the human brains with normal and frontotemporal lobar degeneration with TDP-43 inclusions.</ArticleTitle><Pagination><StartPage>176</StartPage><MedlinePgn>176</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">176</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40478-020-01055-9</ELocationID><Abstract><AbstractText>TAR DNA-binding protein of 43&#xa0;kDa (TDP-43) is a major component of intracellular aggregates formed in brains of the patients with frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS), which are correctively referred to as TDP-43 proteinopathies. A link between Ataxin-2 (ATXN2) and TDP-43 proteinopathies was established when intermediate CAG repeat expansions of ATXN2 gene were found to be associated with ALS and it was shown that ATXN2 modifies TDP-43 toxicity. Although ATXN2's contribution to TDP-43 proteinopathies has been mostly studied in ALS, recent studies have shown that intermediate repeat expansions of ATXN2 also influence the phenotype of FTLD by an unknown mechanism. To address this issue, we immunohistochemically and biochemically analyzed the intracellular dynamics of ATXN2 in brains of normal controls and FTLD-TDP cases. The immunohistochemical studies revealed that ATXN2 localized in the neuronal cytoplasm and proximal dendrites, and expressed widely and uniformly in normal human brains. A semi-quantitative immunofluorescent analysis of normal brains revealed that the cytoplasmic ATXN2 strongly associates with ribosomal protein S6 and poly-A binding protein 1 and partially overlaps with the endoplasmic reticulum marker Calnexin, suggesting a major role of ATXN2 in protein synthesis. The results of immunohistochemical and biochemical analyses of brains from FTLD-TDP cases showed the colocalization of ATXN2 and phosphorylated TDP-43 in the dystrophic neurites and the neuronal cytoplasmic inclusions in the hippocampal region, and a significant reduction of ATXN2 protein compared to controls. These results suggest that ATXN2 is involved in the pathological process of FTLD-TDP. It remains to be clarified whether reduced ATXN2 expression induces neurodegeneration by impairing protein synthesis or plays a neuroprotective role by attenuating the toxicity of TDP-43 aggregates in FTLD-TDP and other TDP-43 proteinopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Ryohei</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, 2-1-1 Kamikitazawa, Setagaya, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higashi</LastName><ForeName>Shinji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Tokyo Medical University Ibaraki Medical Center, 3-20-1 Chuo, Ami, Inashiki, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nonaka</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0830-9403</Identifier><AffiliationInfo><Affiliation>Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya, Tokyo, Japan. nonaka-tk@igakuken.or.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawakami</LastName><ForeName>Ito</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, 2-1-1 Kamikitazawa, Setagaya, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Bank for Aging Research, Department of Neuropathology, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakaecho, Itabashi, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oshima</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, 2-1-1 Kamikitazawa, Setagaya, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niizato</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, 2-1-1 Kamikitazawa, Setagaya, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiyama</LastName><ForeName>Haruhiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Research, Yokohama Brain and Spine Center, 1-2-1 Takigashira, Isogo, Yokohama, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Science of Aging, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Tetsuaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan. 4632tetsu@md.tsukuba.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Neuropathol Commun</MedlineTA><NlmUniqueID>101610673</NlmUniqueID><ISSNLinking>2051-5960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593752">ATXN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067698">Ataxin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593754">Atxn2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067698" MajorTopicYN="N">Ataxin-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Ataxin-2</Keyword><Keyword MajorTopicYN="N">Frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">Localization</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Proteinopathy</Keyword><Keyword MajorTopicYN="N">RNA-binding protein</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>29</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33115537</ArticleId><ArticleId IdType="pmc">PMC7594343</ArticleId><ArticleId IdType="doi">10.1186/s40478-020-01055-9</ArticleId><ArticleId IdType="pii">10.1186/s40478-020-01055-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Bain HDC, Davidson YS, Robinson AC, Ryan S, Rollinson S, Richardson A, et al. The role of lysosomes and autophagosomes in frontotemporal lobar degeneration. Neuropathol Appl Neurobiol. 2019;45(3):244&#x2013;261. doi: 10.1111/nan.12500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12500</ArticleId><ArticleId IdType="pmc">PMC6487817</ArticleId><ArticleId IdType="pubmed">29790198</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakthavachalu B, Huelsmeier J, Sudhakaran IP, Hillebrand J, Singh A, Petrauskas A, et al. RNP-granule assembly via Ataxin-2 disordered domains is required for long-term memory and neurodegeneration. Neuron. 2018;98(4):754&#x2013;766. doi: 10.1016/j.neuron.2018.04.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.04.032</ArticleId><ArticleId IdType="pubmed">29772202</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker IL, Nonis D, Eich F, Klinkenberg M, Gorospe M, K&#xf6;tter P, et al. Mammalian ataxin-2 modulates translation control at the pre-initiation complex via PI3K/mTOR and is induced by starvation. Biochim Biophys Acta. 2016;1862(9):1558&#x2013;1569. doi: 10.1016/j.bbadis.2016.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2016.05.017</ArticleId><ArticleId IdType="pmc">PMC4967000</ArticleId><ArticleId IdType="pubmed">27240544</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544(7650):367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker IL, Nonis D, Nowock J, Auburger G. New alternative splicing variants of the ATXN2 transcript. Neurol Res Pract. 2019;1:22. doi: 10.1186/s42466-019-0025-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42466-019-0025-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. TDP-43: gumming up neurons through protein-protein and protein-RNA interactions. Trends Biochem Sci. 2012;37(6):237&#x2013;247. doi: 10.1016/j.tibs.2012.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2012.03.003</ArticleId><ArticleId IdType="pubmed">22534659</ArticleId></ArticleIdList></Reference><Reference><Citation>Chass&#xe9; H, Boulben S, Costache V, Cormier P, Morales J. Analysis of translation using polysome profiling. Nucleic Acids Res. 2017;45(3):e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5388431</ArticleId><ArticleId IdType="pubmed">28180329</ArticleId></ArticleIdList></Reference><Reference><Citation>Damrath E, Heck MV, Gispert S, Azizov M, Nowock J, Seifried C, et al. ATXN2-CAG42 sequesters PABPC1 into insolubility and induces FBXW8 in cerebellum of old ataxic knock-in mice. PLoS Genet. 2012;8(8):e1002920. doi: 10.1371/journal.pgen.1002920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002920</ArticleId><ArticleId IdType="pmc">PMC3431311</ArticleId><ArticleId IdType="pubmed">22956915</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466(7310):1069&#x2013;1075. doi: 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Fittschen M, Becker IL, Halbach MV, Damrath E, Gispert S, Azizov M, et al. Genetic ablation of ataxin-2 increases several global translation factors in their transcript abundance but decreases translation rate. Neurogenetics. 2015;16(3):181&#x2013;192. doi: 10.1007/s10048-015-0441-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-015-0441-5</ArticleId><ArticleId IdType="pmc">PMC4475250</ArticleId><ArticleId IdType="pubmed">25721894</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier C, Anquetil V, Camuzat A, Stirati-Buron S, Sazdovitch V, Molina-Porcel L, et al. Interrupted CAG expansions in ATXN2 gene expand the genetic spectrum of frontotemporal dementias. Acta Neuropathol Commun. 2018;6:41. doi: 10.1186/s40478-018-0547-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0547-8</ArticleId><ArticleId IdType="pmc">PMC5977499</ArticleId><ArticleId IdType="pubmed">29848387</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero EN, Wang H, Mitra J, Hegde PM, Stowell SE, Liachko NF, et al. TDP-43/FUS in motor neuron disease: complexity and challenges. Prog Neurobiol. 2016;145&#x2013;146:78&#x2013;97. doi: 10.1016/j.pneurobio.2016.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2016.09.004</ArticleId><ArticleId IdType="pmc">PMC5101148</ArticleId><ArticleId IdType="pubmed">27693252</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart MP, Gitler AD. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. J Neurosci. 2012;32(27):9133&#x2013;9142. doi: 10.1523/JNEUROSCI.0996-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0996-12.2012</ArticleId><ArticleId IdType="pmc">PMC3418890</ArticleId><ArticleId IdType="pubmed">22764223</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64(1):60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh DP, Del Bigio MR, Ho DH, Pulst SM. Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer&#x2019;s disease and spinocerebellar ataxia 2. Ann Neurol. 1999;45(2):232&#x2013;241. doi: 10.1002/1531-8249(199902)45:2&lt;232::AID-ANA14&gt;3.0.CO;2-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199902)45:2&lt;232::AID-ANA14&gt;3.0.CO;2-7</ArticleId><ArticleId IdType="pubmed">9989626</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh DP, Figueroa K, Hoang N, Pulst SM. Nuclear localization or inclusion body formation of ataxin-2 Are not necessary for SCA2 pathogenesis in mouse or human. Nat Genet. 2000;26(1):44&#x2013;50. doi: 10.1038/79162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/79162</ArticleId><ArticleId IdType="pubmed">10973246</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh DP, Yang HT, Vakharia H, Nguyen D, Pulst SM. Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. Hum Mol Genet. 2003;12(13):1485&#x2013;1496. doi: 10.1093/hmg/ddg175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddg175</ArticleId><ArticleId IdType="pubmed">12812977</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet. 1996;14(3):285&#x2013;291. doi: 10.1038/ng1196-285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1196-285</ArticleId><ArticleId IdType="pubmed">8896557</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Deerlin VM, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 2015;129(4):469&#x2013;491. doi: 10.1007/s00401-014-1380-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1380-1</ArticleId><ArticleId IdType="pmc">PMC4369168</ArticleId><ArticleId IdType="pubmed">25549971</ArticleId></ArticleIdList></Reference><Reference><Citation>Izumi R, Warita H, Niihori T, Takahashi T, Tateyama M, Suzuki N, et al. Isolated inclusion body myopathy caused by a multisystem proteinopathy-linked hnRNPA1 mutation. Neurol Genet. 2015;1(3):e23. doi: 10.1212/NXG.0000000000000023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000023</ArticleId><ArticleId IdType="pmc">PMC4809462</ArticleId><ArticleId IdType="pubmed">27066560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Kook MC, Shin YK, Park SH, Song HG. Evaluation of antigen retrieval buffer systems. J Mol Histol. 2004;35:409&#x2013;416. doi: 10.1023/B:HIJO.0000039854.17808.e0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:HIJO.0000039854.17808.e0</ArticleId><ArticleId IdType="pubmed">15503815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Millecamps S, Stevanin G, Rivaud-P&#xe9;choux S, Moigneu C, Camuzat A, et al. Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders. Neurology. 2014;83(11):990&#x2013;995. doi: 10.1212/WNL.0000000000000778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000778</ArticleId><ArticleId IdType="pmc">PMC4162303</ArticleId><ArticleId IdType="pubmed">25098532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T, Li YR, Ingre C, Weber M, Grehl T, Gredal O, et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet. 2011;20(9):1697&#x2013;1700. doi: 10.1093/hmg/ddr045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr045</ArticleId><ArticleId IdType="pmc">PMC3071667</ArticleId><ArticleId IdType="pubmed">21292779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, Cali CP, Lee EB. RNA metabolism in neurodegenerative disease. Dis Model Mech. 2017;10:509&#x2013;518. doi: 10.1242/dmm.028613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.028613</ArticleId><ArticleId IdType="pmc">PMC5451173</ArticleId><ArticleId IdType="pubmed">28468937</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Masuda-Suzukake M, Arai T, Hasegawa Y, Akatsu H, Obi T, et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 2013;4(1):124&#x2013;134. doi: 10.1016/j.celrep.2013.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.06.007</ArticleId><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonhoff U, Ralser M, Welzel F, Piccini I, Balzereit D, Yaspo ML, et al. Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol Biol Cell. 2007;18(4):1385&#x2013;1396. doi: 10.1091/mbc.e06-12-1120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e06-12-1120</ArticleId><ArticleId IdType="pmc">PMC1838996</ArticleId><ArticleId IdType="pubmed">17392519</ArticleId></ArticleIdList></Reference><Reference><Citation>Panda AC, Martindale JL, Gorospe M. Polysome fractionation to analyze mRNA distribution profiles. Biol Protoc. 2017;7(3):e2126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5431591</ArticleId><ArticleId IdType="pubmed">28516123</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker SS, Krantz J, Kwak EA, Barker NK, Deer CG, Lee NY, et al. Insulin induces microtubule stabilization and regulates the microtubule plus-end tracking protein network in adipocytes. Mol Cell Proteomics. 2019;18(7):1363&#x2013;1381. doi: 10.1074/mcp.RA119.001450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.RA119.001450</ArticleId><ArticleId IdType="pmc">PMC6601206</ArticleId><ArticleId IdType="pubmed">31018989</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Ravenscroft TA, Sanchez-Contreras M, Rademakers R. Genetics of FTLD: overview and what else we can expect from genetic studies. J Neurochem. 2016;138(Suppl 1):32&#x2013;53. doi: 10.1111/jnc.13622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13622</ArticleId><ArticleId IdType="pubmed">27009575</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralser M, Albrecht M, Nonhoff U, Lengauer T, Lehrach H, Krobitsch S. An integrative approach to gain insights into the cellular function of human ataxin-2. J Mol Biol. 2005;346(1):203&#x2013;214. doi: 10.1016/j.jmb.2004.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2004.11.024</ArticleId><ArticleId IdType="pubmed">15663938</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino E, Mancini C, Boschi S, Ferrero P, Ferrone M, Bianca S, et al. ATXN2 intermediate repeat expansions influence the clinical phenotype in frontotemporal dementia. Neurobiol Aging. 2019;73:231.e7&#x2013;231.e9. doi: 10.1016/j.neurobiolaging.2018.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.09.009</ArticleId><ArticleId IdType="pubmed">30342763</ArticleId></ArticleIdList></Reference><Reference><Citation>Satterfield TF, Pallanck LJ. Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes. Hum Mol Genet. 2006;15(16):2523&#x2013;2532. doi: 10.1093/hmg/ddl173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddl173</ArticleId><ArticleId IdType="pubmed">16835262</ArticleId></ArticleIdList></Reference><Reference><Citation>Seltman RE, Matthews BR. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs. 2012;26(10):841&#x2013;870. doi: 10.2165/11640070-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11640070-000000000-00000</ArticleId><ArticleId IdType="pubmed">22950490</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefani G, Fraser CE, Darnell JC, Darnell RB. Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells. J Neurosci. 2004;24(33):7272&#x2013;7276. doi: 10.1523/JNEUROSCI.2306-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2306-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729764</ArticleId><ArticleId IdType="pubmed">15317853</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR. Motor neuron disease: biomarker development for an expanding cerebral syndrome. Clin Med (Lond) 2016;16(Suppl 6):s60&#x2013;s65. doi: 10.7861/clinmedicine.16-6-s60.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmedicine.16-6-s60</ArticleId><ArticleId IdType="pmc">PMC6329564</ArticleId><ArticleId IdType="pubmed">27956443</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack GE, Luisier R, Taha DM, Neeves J, Modic M, Mitchell JS, et al. Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain. 2019;142(9):2572&#x2013;2580. doi: 10.1093/brain/awz217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz217</ArticleId><ArticleId IdType="pmc">PMC6735815</ArticleId><ArticleId IdType="pubmed">31368485</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Loo S, Eich F, Nonis D, Auburger G, Nowock J. Ataxin-2 associates with rough endoplasmic reticulum. Exp Neurol. 2009;215(1):110&#x2013;118. doi: 10.1016/j.expneurol.2008.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.09.020</ArticleId><ArticleId IdType="pubmed">18973756</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>